Technetium Tc 99m-labeled Tilmanocept · Lymphoseek, Tc99m

What is Technetium Tc 99m-labeled Tilmanocept?

Technetium Tc 99m-labeled tilmanocept (Lymphoseek) is a radioactive diagnostic agent consisting of a dextran backbone conjugated with mannose and DTPA chelating agent labeled with technetium Tc 99m. It binds to CD206 mannose receptors on macrophages and dendritic cells in lymphatic tissue, enabling lymph node imaging and intraoperative localization during cancer surgery.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Lymphoseek, Tc99m, 99m Tc-TM

Drug type

Radiopharmaceutical

Targets

CD206 (MSR1)

Mechanism

Acts on CD206 (MSR1)

Therapy area

Oncology

Developer

Cardinal Health 414 (CAH)

FDA status

Approved as Lymphoseek (March 13, 2013), NDA202207 · FDA label

✅ FDA-approved uses

• Lymphatic mapping to locate lymph nodes draining a primary tumor site in solid tumors
• Guiding sentinel lymph node biopsy in clinically node negative squamous cell carcinoma of the oral cavity
• Guiding sentinel lymph node biopsy in breast cancer
• Guiding sentinel lymph node biopsy in melanoma

From the indications section of the FDA label (version of Aug 28, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Anal CancerBreast CancerEndometrial CancerMelanomaRhabdomyosarcoma

Sources

• FDA label (DailyMed)
• FDA label Lymphoseek (2026-08-28), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT02509598
• ClinicalTrials.gov NCT05236387

Updated Oct 3, 2026. Something wrong or missing? Report it on the CAH page.